Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

References

• BhanjiNHChouinardGMargoleseHCA review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophreniaEur Neuropsychopharmacol2004142879215013023
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcevoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• ValensteinMGanoczyDMccarthyJFMyra KimHLeeTABlowFCAntipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective reviewJ Clin Psychiatry200667101542155017107245
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPS2004558886891
   Google Scholar
• DoeringSMüllerEKöpckeWPredictors of relapse and rehospitalization in schizophrenia and schizoaffective disorderSchizophr Bull199824187989502548
   PubMed Web of Science ®Google Scholar
• KnappMKingDPugnerKLapuertaPNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry20041840650951615172945
   PubMed Web of Science ®Google Scholar
• RauchASFleischhackerWWLong-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspectiveCNS Drugs201327863765223780619
   PubMed Web of Science ®Google Scholar
• EmsleyROosthuizenPKoenLNiehausDJMedoriRRabinowitzJOral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studiesClin Ther200830122378238619167596
   PubMed Web of Science ®Google Scholar
• Invega Sustenna® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [prescribing information]USAJanseen Pharmaceutical Companies2015
   Google Scholar
• Invega Trinza® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [prescribing information]USAJanseen Pharmaceutical Companies2015
   Google Scholar
• TREVICTA (paliperidone palmitate) [summary of product characteristics]BelgiumJanseen Pharmaceutica NV2014
   Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trialJAMA Psychiatry201572883083925820612
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, Noninferiority studyInt J Neuropsychopharmacol2016197pii:pyw018
   Web of Science ®Google Scholar
• BanerjeeAACross-cultural variance of schizophrenia in symptoms diagnosis and treatmentThe Georgetown Undergrad J Health Sci2012621824
   Google Scholar
• BauerSMSchandaHKarakulaHCulture and the prevalence of hallucinations in schizophreniaCompr Psychiatry201152331932521497227
   PubMed Web of Science ®Google Scholar
• StaufferVLSniadeckiJLPiezerKWImpact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorderBMC Psychiatry20101018921047395
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• GuyWECDEU assessment manual for psychopharmacologyU S Department of Health, and Welfare1976534537
   Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: Subgroup analysis of a global, randomized, double-blind, phase III, noninferiority studyNeuropsychiatr Dis Treat2017132193220728860777
   PubMed Web of Science ®Google Scholar
• CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry20121212622455454
   PubMed Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol201125568569720615933
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of pali-peridone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• DayabandaraMHanwellaRRatnatungaSSeneviratneSSuraweeraCde SilvaVAAntipsychotic-associated weight gain: management strategies and impact on treatment adherenceNeuropsychiatr Dis Treat2017132231224128883731
   PubMed Web of Science ®Google Scholar
• VandenbergheFGholam-RezaeeMSaigí-MorguiNImportance of early weight changes to predict long-term weight gain during psychotropic drug treatmentJ Clin Psychiatry20157611e1417e142326646038
   PubMed Web of Science ®Google Scholar
• BusheCJSlooffCJHaddadPMKaragianisJLWeight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes databaseJ Psychopharmacol201327435836523343595
   PubMed Web of Science ®Google Scholar
• BaileySDXieCParéGVariation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMIDiabetologia201457473874524362726
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• TakahashiNTakahashiMSaitoTRandomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophreniaNeuropsychiatr Dis Treat201391889189824353421
   PubMed Web of Science ®Google Scholar